Where is Chiesi based?

Parma, Italy
Chiesi worldwide Chiesi Farmaceutici S.p.A. is an international, research-based, pharmaceutical company, based in Parma, Italy.

Who owns Chiesi group?

Chiesi Farmaceutici

Type	Società per Azioni, (S.p.A.) (something like a Joint-Stock company)
Industry	Pharmaceuticals
Founded	1935
Headquarters	Parma , Italy
Key people	Alberto Chiesi (President) Paolo Chiesi (Vice-president) Ugo Di Francesco (CEO)

What does chiesi make?

CHIESI GROUP The privately owned company has a strong focus on research, development, production and the commercialization of innovative medicines in therapeutic areas that include: respiratory, cardiovascular, neonatology, and cystic fibrosis.

How big is Chiesi?

The Chiesi Group currently employs 6,389 people worldwide, 2,119 of whom are in Italy and has a turnover of € 2 billion 229 million. Chiesi’s business comprises 30 affiliates, 7 research centres, 3 production sites and a commercial presence in a total of 90 countries.

What does Viatris Inc do?

Products. The company produces and sells a variety of medicines, with 1,400 approved therapeutic molecules in its portfolio. It owns brands (like Viagra, Xanax, Lipitor), generics, including branded and complex generics, biosimilars, and over-the-counter (OTC) drugs and active pharmaceutical ingredients.

Is Chiesi a good place to work?

92% of employees at Chiesi USA Inc. say it is a great place to work compared to 57% of employees at a typical U.S.-based company.

Is Viatris a good investment?

Viatris Inc’s trailing 12-month revenue is $17.6 billion with a 1.0% profit margin. Year-over-year quarterly sales growth most recently was -5.4%. Analysts expect adjusted earnings to reach $3.481 per share for the current fiscal year. Viatris Inc currently has a 4.5% dividend yield.

Does Viatris belong Pfizer?

Pfizer recently completed a spin-off of it’s Upjohn business, combining it with Mylan N.V. to form a new entity, Viatris, which began trading on 11/16/2020 under the ticker symbol VTRS. Mylan N.V. was delisted from the Nasdaq stock exchange as a result of this corporate action and is no longer tradeable.

Should I sell my VTRS stock?

There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should “hold” Viatris stock.

Why is Viatris stock so cheap?

Generic drug manufacturers are capable of making highly consistent cash flows over time. Viatris is valued cheaply, and its dividend payout is growing.

Should I buy Viatris stock?

1. Sales are flat. The biggest reason to consider selling Viatris stock right now is that revenue growth failed to materialize in 2021. Its total net revenue dropped by 4% last year compared to 2020, reaching $17.8 billion.

Is Viatris an American company?

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania. The company was formed through the merger of Mylan and Upjohn, a division of Pfizer, on November 16, 2020.

Is Viatris a good buy now?

Is Viatris stock a good value?

Currently, Viatris Inc’s price-earnings ratio is 78.2. Viatris Inc’s trailing 12-month revenue is $17.6 billion with a 1.0% profit margin. Year-over-year quarterly sales growth most recently was -5.4%. Analysts expect adjusted earnings to reach $3.483 per share for the current fiscal year.

Should I sell my Viatris stock?

Is Viatris worth buying?

Viatris Inc currently has a 4.0% dividend yield. The continuous implementation of new and innovative therapies, favorable mergers and acquisitions (M&A) activities and low occurrence of patent cliffs are all strong drivers of sales growth for 2021.

Does Viatris pay a dividend?

PITTSBURGH, Jan. 6, 2022 /PRNewswire/ — Viatris Inc. (NASDAQ: VTRS) today announced that on Tuesday, January 4, its Board of Directors approved a 9% increase in its quarterly dividend and declared a dividend for the first quarter of 2022 of 12 cents ($0.12) per share on outstanding common stock.

Is Pfizer and Viatris same company?

Viatris was formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.

Will VTRS pay a dividend in 2021?

VTRS Dividend History

Ex/EFF DATE	TYPE	PAYMENT DATE
02/23/2022	CASH	03/16/2022
11/22/2021	CASH	12/16/2021
08/23/2021	CASH	09/16/2021
05/21/2021	CASH	06/16/2021

Is Viatris a spin-off of Pfizer?